Literature DB >> 10400555

Hepatitis C prevalence and risk factors in the northern Alberta dialysis population.

J Sandhu1, J K Preiksaitis, P M Campbell, K C Carriere, P A Hessel.   

Abstract

Hepatitis C virus (HCV) is an emerging global public health issue with particular relevance in multiply transfused renal dialysis patients. This cross-sectional study evaluated the prevalence and risk factors for HCV infection among renal dialysis patients in northern Alberta, Canada. Ninety-two percent of eligible patients (n = 336) provided informed consent to participate. Participants were interviewed to gather risk factor information and, using multiple logistic regression analysis with exact inference, a predictive model for HCV infection in this population was developed. The prevalence of HCV infection in the population was 6.5%, and all positive patients had at least one identifiable risk factor. The multivariate analysis showed that the risk of HCV infection was greater for those in the 18-55 years age category (odds ratio (OR) = 4.9, 95% confidence interval (CI) 1.2-27.9), patients who had been on dialysis > 5 years (OR = 3.7, 95% CI 1.2-12.0), and patients who had > or = 2 high risk life-style behaviors (OR = 5.0, 95% CI 1.5-16.7). Transfusion prior to 1990 was marginally associated with HCV status (OR = 4.0, 95% CI 0.96-16.3). This study documented previously unreported life-style risk factors for HCV infection in patients with renal failure, confirmed the expected decline in transfusion-acquired HCV infection in this population, and provided evidence against nosocomial transmission of HCV.

Entities:  

Mesh:

Year:  1999        PMID: 10400555     DOI: 10.1093/oxfordjournals.aje.a009919

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  9 in total

Review 1.  Current status of hepatitis C in Canada.

Authors:  S Zou; M Tepper; A Giulivi
Journal:  Can J Public Health       Date:  2000 Jul-Aug

Review 2.  Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation.

Authors:  Lucy Somerville; Karen Doucette
Journal:  Curr Infect Dis Rep       Date:  2018-05-22       Impact factor: 3.725

Review 3.  Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

4.  Prevalence and incidence of hepatitis C virus in hemodialysis patients in British Columbia: Follow-up after a possible breach in hemodialysis machines.

Authors:  Andrew W Tu; Jane A Buxton; Mandy Whitlock; Ognjenka Djurdjev; Mei Chong; Mel Krajden; Monica Beaulieu; Adeera Levin
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

5.  Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients.

Authors:  H Hinrichsen; G Leimenstoll; G Stegen; H Schrader; U R Fölsch; W E Schmidt
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

6.  The prevalence of HCV antibodies in skin disease patients in Saudi Arabia.

Authors:  Mona Halawani; Amal Balbisi; Hend Alotaibi; Fahed Alsaif; Talal M Bakir
Journal:  Saudi Pharm J       Date:  2009-12-24       Impact factor: 4.330

7.  Guidance on the use of increased infectious risk donors for organ transplantation.

Authors: 
Journal:  Transplantation       Date:  2014-08-27       Impact factor: 4.939

8.  Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance.

Authors:  L J Yee; H L Weiss; R G Langner; J Herrera; R A Kaslow; D J van Leeuwen
Journal:  BMC Infect Dis       Date:  2001-07-24       Impact factor: 3.090

9.  Risk factors of HCV seroconversion in hemodialysis patients in tabriz, iran.

Authors:  Mohammad Hossein Somi; Jalal Etemadi; Morteza Ghojazadeh; Sara Farhang; Mehrasa Faramarzi; Sanaz Foroutan; Maryam Soleimanpour
Journal:  Hepat Mon       Date:  2014-06-01       Impact factor: 0.660

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.